Marksans Pharma spurts 3% after USFDA approval

India Infoline News Service | Mumbai | October 18, 2016 12:02 IST

The scrip opened at Rs 53.5 and has touched a high and low of Rs 56 and Rs 53.1 respectively.

Marksans Pharma
Marksans Pharma Ltd is currently trading at Rs 54.85, up by Rs 1.6 or 3% from its previous closing of Rs 53.25 on the BSE  after the U.S. Food and Drug Administration approved its abbreviated new drug application for paricalcitol capsules. Paricalcitol capsules, which are a Vitamin D compound, are used to prevent and treat high levels of parathyroid hormone in certain patients with chronic kidney disease.

The scrip opened at Rs 53.5 and has touched a high and low of Rs 56 and Rs 53.1 respectively.

So far 4835826 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 2179.6 crore.

The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 113.8 on 28-Dec-2015 and a 52 week low of Rs 33.45 on 01-Mar-2016. Last one week high and low of the scrip stood at Rs 54.2 and Rs 51.2 respectively.

The promoters holding in the company stood at 48.25 % while Institutions and Non-Institutions held 13.77 % and 37.98 % respectively.

The stock is currently trading above its 200 DMA.

***Note: This is a NSE Chart

 

Advertisements

  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get IIFL express personal loan disbursal in just 8* hours...Know More
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.